Treatment of refractory polymyalgia rheumatica with etanercept: An open pilot study

Maria Grazia Catanoso, Pierluigi Macchioni, Luigi Boiardi, Nicolò Pipitone, Carlo Salvarani

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective. To investigate whether etanercept has a steroid-sparing effect in the treatment of patients with relapsing polymyalgia rheumatica (PMR). Methods. The study group comprised patients with relapsing PMR who were not able to reduce their prednisone dosage below 7.5-10 mg/day and who had experienced corticosteroid-related side effects. Patients received injections of etanercept 25 mg twice weekly for 24 weeks, and were followed up for 3 additional months after treatment withdrawal. Patients regularly underwent clinical assessment, measurement of erythrocyte sedimentation rate and C-reactive protein level, and ultrasound (US) examination of the shoulders during the 9 months of the followup period. Results. All 6 enrolled patients responded to etanercept with sustained remission (improvement of at least 70% according to European League Against Rheumatism response criteria for PMR in 4 patients and at least 50% in 2 patients) and were able to significantly reduce their median prednisone daily dosage without experiencing a disease relapse (8.75 mg versus 2.5 mg; P = 0.026) at the end of the 9-month study period. US shoulder examination performed at the end of followup demonstrated a parallel reduction of glenohumeral and periarticular inflammation. A significant reduction in the cumulative prednisone dose 9 months before versus the 9-month study period was observed (mean ± SD 1,767 ± 524 mg versus 730 ± 182 mg; P = 0.028). Three patients developed nonsevere side effects: bacterial cystitis in 2 and influenza in 1. Conclusion. These results, which should be confirmed in a controlled study, suggest that etanercept may be a safe and useful corticosteroid-sparing agent in relapsing PMR.

Original languageEnglish
Pages (from-to)1514-1519
Number of pages6
JournalArthritis Care and Research
Volume57
Issue number8
DOIs
Publication statusPublished - Dec 15 2007

Fingerprint

Polymyalgia Rheumatica
Prednisone
Therapeutics
Adrenal Cortex Hormones
Cystitis
Etanercept
Blood Sedimentation
C-Reactive Protein
Human Influenza
Steroids
Inflammation
Recurrence
Injections

Keywords

  • Corticosteroid
  • Etanercept
  • Polymyalgia rheumatica

ASJC Scopus subject areas

  • Rheumatology

Cite this

Treatment of refractory polymyalgia rheumatica with etanercept : An open pilot study. / Catanoso, Maria Grazia; Macchioni, Pierluigi; Boiardi, Luigi; Pipitone, Nicolò; Salvarani, Carlo.

In: Arthritis Care and Research, Vol. 57, No. 8, 15.12.2007, p. 1514-1519.

Research output: Contribution to journalArticle

Catanoso, Maria Grazia ; Macchioni, Pierluigi ; Boiardi, Luigi ; Pipitone, Nicolò ; Salvarani, Carlo. / Treatment of refractory polymyalgia rheumatica with etanercept : An open pilot study. In: Arthritis Care and Research. 2007 ; Vol. 57, No. 8. pp. 1514-1519.
@article{0f6edf8e46754af0b729ec1dd02f6dec,
title = "Treatment of refractory polymyalgia rheumatica with etanercept: An open pilot study",
abstract = "Objective. To investigate whether etanercept has a steroid-sparing effect in the treatment of patients with relapsing polymyalgia rheumatica (PMR). Methods. The study group comprised patients with relapsing PMR who were not able to reduce their prednisone dosage below 7.5-10 mg/day and who had experienced corticosteroid-related side effects. Patients received injections of etanercept 25 mg twice weekly for 24 weeks, and were followed up for 3 additional months after treatment withdrawal. Patients regularly underwent clinical assessment, measurement of erythrocyte sedimentation rate and C-reactive protein level, and ultrasound (US) examination of the shoulders during the 9 months of the followup period. Results. All 6 enrolled patients responded to etanercept with sustained remission (improvement of at least 70{\%} according to European League Against Rheumatism response criteria for PMR in 4 patients and at least 50{\%} in 2 patients) and were able to significantly reduce their median prednisone daily dosage without experiencing a disease relapse (8.75 mg versus 2.5 mg; P = 0.026) at the end of the 9-month study period. US shoulder examination performed at the end of followup demonstrated a parallel reduction of glenohumeral and periarticular inflammation. A significant reduction in the cumulative prednisone dose 9 months before versus the 9-month study period was observed (mean ± SD 1,767 ± 524 mg versus 730 ± 182 mg; P = 0.028). Three patients developed nonsevere side effects: bacterial cystitis in 2 and influenza in 1. Conclusion. These results, which should be confirmed in a controlled study, suggest that etanercept may be a safe and useful corticosteroid-sparing agent in relapsing PMR.",
keywords = "Corticosteroid, Etanercept, Polymyalgia rheumatica",
author = "Catanoso, {Maria Grazia} and Pierluigi Macchioni and Luigi Boiardi and Nicol{\`o} Pipitone and Carlo Salvarani",
year = "2007",
month = "12",
day = "15",
doi = "10.1002/art.23095",
language = "English",
volume = "57",
pages = "1514--1519",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Treatment of refractory polymyalgia rheumatica with etanercept

T2 - An open pilot study

AU - Catanoso, Maria Grazia

AU - Macchioni, Pierluigi

AU - Boiardi, Luigi

AU - Pipitone, Nicolò

AU - Salvarani, Carlo

PY - 2007/12/15

Y1 - 2007/12/15

N2 - Objective. To investigate whether etanercept has a steroid-sparing effect in the treatment of patients with relapsing polymyalgia rheumatica (PMR). Methods. The study group comprised patients with relapsing PMR who were not able to reduce their prednisone dosage below 7.5-10 mg/day and who had experienced corticosteroid-related side effects. Patients received injections of etanercept 25 mg twice weekly for 24 weeks, and were followed up for 3 additional months after treatment withdrawal. Patients regularly underwent clinical assessment, measurement of erythrocyte sedimentation rate and C-reactive protein level, and ultrasound (US) examination of the shoulders during the 9 months of the followup period. Results. All 6 enrolled patients responded to etanercept with sustained remission (improvement of at least 70% according to European League Against Rheumatism response criteria for PMR in 4 patients and at least 50% in 2 patients) and were able to significantly reduce their median prednisone daily dosage without experiencing a disease relapse (8.75 mg versus 2.5 mg; P = 0.026) at the end of the 9-month study period. US shoulder examination performed at the end of followup demonstrated a parallel reduction of glenohumeral and periarticular inflammation. A significant reduction in the cumulative prednisone dose 9 months before versus the 9-month study period was observed (mean ± SD 1,767 ± 524 mg versus 730 ± 182 mg; P = 0.028). Three patients developed nonsevere side effects: bacterial cystitis in 2 and influenza in 1. Conclusion. These results, which should be confirmed in a controlled study, suggest that etanercept may be a safe and useful corticosteroid-sparing agent in relapsing PMR.

AB - Objective. To investigate whether etanercept has a steroid-sparing effect in the treatment of patients with relapsing polymyalgia rheumatica (PMR). Methods. The study group comprised patients with relapsing PMR who were not able to reduce their prednisone dosage below 7.5-10 mg/day and who had experienced corticosteroid-related side effects. Patients received injections of etanercept 25 mg twice weekly for 24 weeks, and were followed up for 3 additional months after treatment withdrawal. Patients regularly underwent clinical assessment, measurement of erythrocyte sedimentation rate and C-reactive protein level, and ultrasound (US) examination of the shoulders during the 9 months of the followup period. Results. All 6 enrolled patients responded to etanercept with sustained remission (improvement of at least 70% according to European League Against Rheumatism response criteria for PMR in 4 patients and at least 50% in 2 patients) and were able to significantly reduce their median prednisone daily dosage without experiencing a disease relapse (8.75 mg versus 2.5 mg; P = 0.026) at the end of the 9-month study period. US shoulder examination performed at the end of followup demonstrated a parallel reduction of glenohumeral and periarticular inflammation. A significant reduction in the cumulative prednisone dose 9 months before versus the 9-month study period was observed (mean ± SD 1,767 ± 524 mg versus 730 ± 182 mg; P = 0.028). Three patients developed nonsevere side effects: bacterial cystitis in 2 and influenza in 1. Conclusion. These results, which should be confirmed in a controlled study, suggest that etanercept may be a safe and useful corticosteroid-sparing agent in relapsing PMR.

KW - Corticosteroid

KW - Etanercept

KW - Polymyalgia rheumatica

UR - http://www.scopus.com/inward/record.url?scp=37349129647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349129647&partnerID=8YFLogxK

U2 - 10.1002/art.23095

DO - 10.1002/art.23095

M3 - Article

C2 - 18050171

AN - SCOPUS:37349129647

VL - 57

SP - 1514

EP - 1519

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 8

ER -